With the latest additions and improvements to Tapestri’s capabilities, researchers of hematologic oncology can now access single-cell insights from as few as 20,000 cells, while conserving precious samples. Get up and running quickly with single-cell experiments with our expanded menu for hematologic malignancies. Now you can do more single cell in less time with lower sample input, enabling new avenues for your research that were previously impossible.
With our new input requirements down to as few as 20,000 cells, perform single-cell analysis on projects where it wasn’t previously possible, all the while conserving precious samples. Get insights from low input samples without sacrificing performance and the ability to detect rare cells.
Get up and running quickly and conveniently thanks to pre-designed panels for heme malignancies. The new Tapestri Single-cell DNA Published Panels are sourced from leading researchers covering various indications. These have been featured in peer-reviewed publications, verifying performance.
For simultaneous single-cell DNA and protein analysis, configure your own antibody cocktail from a growing catalog of pre-optimized antibody oligonucleotide conjugates (AOC). Or, start with the pre-designed 45-protein TotalSeq™-D Heme Oncology Cocktail, and then spike in additional AOCs to fit your research needs. TotalSeq™ oligo-conjugated antibodies from BioLegend integrate seamlessly into the Tapestri single-cell DNA sequencing workflow to amplify the power of single-cell analysis.
Profiling hematologic malignancies using single-cell analysis lends insight into how we can better detect and surveil disease, segment patients into clinical trials, and combat resistance to therapies. Investigators have been using the Tapestri Platform to make strides in hematologic oncology research, with breakthrough applications including therapy resistance, clonal hematopoiesis of indeterminate potential (CHIP), and minimal residual disease (MRD). For example, single-cell DNA + protein multi-omics can be leveraged to distinguish MRD from CHIP clones.